Comparative Pharmacology
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus BENTYL PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus BENTYL PRESERVATIVE FREE.
ANISOTROPINE METHYLBROMIDE vs BENTYL PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anisotropine methylbromide is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors (M1, M2, M3), thereby inhibiting parasympathetic nerve impulses. This leads to relaxation of smooth muscle in the gastrointestinal tract, decreased gastric acid secretion, and reduced motility.
Dicyclomine is a muscarinic acetylcholine receptor antagonist (anticholinergic) that inhibits the action of acetylcholine on structures innervated by postganglionic parasympathetic nerves. It reduces smooth muscle spasm in the gastrointestinal tract by blocking M1, M2, and M3 receptors, with a predominant effect on M3 receptors in the gut.
Adult: 1-2 mg intramuscularly or subcutaneously every 4-6 hours as needed. Maximum: 8 mg/day.
20 mg orally three times daily; may increase to 40 mg three times daily if tolerated.
None Documented
None Documented
Clinical Note
moderateAnisotropine methylbromide + Fesoterodine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Fesoterodine."
Clinical Note
moderateAnisotropine methylbromide + Quinidine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Quinidine."
Clinical Note
moderateAnisotropine methylbromide + Topiramate
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Topiramate."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5-2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours).
Terminal elimination half-life: 1.9–3.3 hours (in healthy adults). Clinically, short half-life necessitates frequent dosing for sustained effect.
Primarily renal (approx. 70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%, mainly as metabolites.
Renal: ~50% (mostly as metabolites), Biliary/Fecal: ~40% (as unchanged drug and metabolites), minor via enterohepatic circulation.
Category C
Category C
Anticholinergic
Anticholinergic
Anisotropine methylbromide + Methadone
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Methadone."